May 14, 2020 / 11:29 AM / 18 days ago

BRIEF-Inovio Says 85% Of Glioblastoma Patients Treated With INO-5401 Combined with Libtayo Alive for at least 12 Months

May 14 (Reuters) - Inovio Pharmaceuticals Inc:

* INOVIO’S INO-5401 IN COMBINATION WITH PD-1 INHIBITOR LIBTAYO® (CEMIPLIMAB) DEMONSTRATES 85% OF NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS ARE ALIVE 12 MONTHS FOLLOWING TREATMENT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below